Check patentability & draft patents in minutes with Patsnap Eureka AI!

A kind of preparation method of tenofovir alafenamide intermediate

A technology for tenofovir alafenamide and intermediates, which is applied in the field of preparation of tenofovir alafenamide intermediates, can solve the problems of long synthesis route, difficult handling, and difficult removal, etc., and achieves the availability of raw materials High, less by-products, easy to handle

Active Publication Date: 2022-07-05
LUNAN BETTER PHARMA
View PDF15 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0024] (1) The use of materials such as DCC and DMAP produces a large amount of waste, which is easy to remain in the product and difficult to remove;
[0025] (2) Use a large amount of organic bases such as triethylamine and pyridine, which are highly toxic, difficult to reprocess, and unfriendly to the environment;
[0026] (3) The raw material of large batches is difficult to obtain in the hydrolysis method, and synthetic route is longer;
[0027] (4) If the feeding ratio is too large or the amount of solvent is too much, post-processing will produce a large amount of waste liquid, which is difficult to handle and will cause great environmental pollution.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of preparation method of tenofovir alafenamide intermediate
  • A kind of preparation method of tenofovir alafenamide intermediate
  • A kind of preparation method of tenofovir alafenamide intermediate

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0080] Compound II (100.00 g, 348.17 mmol) and acetone (300 ml) were added to the reaction flask, and stirred at room temperature to obtain a white slurry. Sodium carbonate (20.30g, 191.49mmol) was prepared into a saturated aqueous solution, slowly dripped into the above-mentioned white slurry, the reaction solution was gradually dissolved and released a large amount of gas, 30 ℃ of thermal insulation stirring reactions were completely dissolved and no gas was generated, and continued thermal insulation stirring for 1 ~2 hours, after the reaction is completed, add acetone (1000 ml), drop to 0 °C and stir for half an hour, filter with suction, wash with an appropriate amount of acetone, and vacuum dry at 70 °C to obtain white solid compound Ia-1 (monosodium salt), yield 97.6 %, HPLC: 99.650%, Na content 7.45%.

Embodiment 2

[0082] Compound II (100.00 g, 348.17 mmol) and methanol (300 ml) were added to the reaction flask, and stirred at room temperature to obtain a white slurry. Add purified water (80ml), sodium bicarbonate (35.10g, 417.80mmol) is added to the above-mentioned white slurry in batches, the reaction solution gradually dissolves and emits a large amount of gas, 55 ℃ of insulation stirring reactions are completely dissolved and no gas is generated, continue Insulation and stirring 1~2, after the reaction finishes, add acetone (1000ml), cool down at 0 ℃ and stir with suction for half an hour, wash with an appropriate amount of acetone, and vacuum dry at 70 ℃ to obtain white solid compound Ia-1 (mainly monosodium salt, containing A small amount of disodium salt), yield 91.2%, HPLC: 99.591%, Na content 8.20%.

Embodiment 3

[0084] Compound II (100.00 g, 348.17 mmol) and acetone (300 ml) were added to the reaction flask, and stirred at room temperature to obtain a white slurry. Sodium hydroxide (14.00g, 350.03mmol) was prepared into a saturated aqueous solution, slowly dropped into the above-mentioned white slurry, the reaction was stirred at 30° C., the reaction solution was gradually dissolved, and the stirring was continued for 1 to 2 hours. After the reaction, acetone was added. (1200ml), drop to 0°C and stir for half an hour, filter with suction, wash with appropriate amount of acetone, and vacuum dry at 70°C to obtain white solid compound Ia-1 (monosodium salt), yield 95.7%, HPLC: 99.382%, Na content 7.42 %.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
wavelengthaaaaaaaaaa
Login to View More

Abstract

The invention belongs to the technical field of medicinal chemistry, and provides a method for preparing a tenofovir alafenamide intermediate. Tenofovir is used as a raw material and reacted with an alkali metal base or salt to generate a tenofovir alkali metal monosalt , and then react with triphenyl phosphite to generate the target intermediate; the method has simple reaction conditions, high raw material availability, high yield and high purity, reduces the use of a large amount of organic bases, produces less waste liquid, and causes little environmental pollution. Suitable for industrial production.

Description

technical field [0001] The invention belongs to the technical field of medicinal chemistry, in particular to a preparation method of a tenofovir alafenamide intermediate. Background technique [0002] Tenofovir alafenamide fumarate, chemical name 9-[(R)-2-[[(S)-[[(S)-1-(isopropoxycarbonyl) Ethyl]amino]phenoxyphosphinyl]methoxy]propyl]adenine fumarate, is a new type of nucleotide reverse transcriptase inhibitor, its chemical structure is as follows: [0003] [0004] The compound was developed by Gilead Sciences in the United States and was approved by the U.S. FDA in November 2016 under the trade name Vem1idy. As an oral nucleotide reverse transcriptase inhibitor, it is another prodrug of tenofovir disoproxil fumarate (TDF) for hepatitis B virus infection (HBV) and acquired immune syndrome ( HIV). This product is rapidly converted into tenofovir after oral administration, and is phosphorylated to tenofovir diphosphate under the action of cellular kinases, which inhibit...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07F9/6561
CPCC07F9/65616
Inventor 刘成利薛飞刘忠
Owner LUNAN BETTER PHARMA
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More